股票 
板块 
用户 
资讯 11月5日，上海美迪西生物医药股份有限公司上市七周年之际，美迪西与上海戊碳源生物科技有限公司正式签署战略合作协议。双方将围绕戊碳源代谢疾病小核酸药物管线的临床前药代动力学与安全性评价研究展开深度合作，美迪西将提供覆盖非临床研究及IND申报支持的一站式服务，加速推动高校源头创新成果向临床阶段转化。
从实验室到IND：
一场高校成果转化的“关键一跃”
戊碳源成立于2026年1月，由上海交通大学医学院知名教授与资深药物研发人员联合创立。公司创始团队依托20年基础研究的深厚积累，并结合小核酸的药物形式，开发通过能量疏导的全新机制小核酸药物，满足代谢类疾病领域未被满足的临床需求。公司核心管线将针对肥胖治疗与代谢功能障碍相关脂肪性肝炎（MASH）。这一“从基础机制到候选分子”的路径，使戊碳源成为高校原始创新走向产业化的典型样本。
陈春麟 博士
美迪西创始人、董事长&CEO
高校和科研院所是创新药最早的源头。我自己也做过教授，深知从实验室发现到候选药物之间那段路有多难。美迪西想做的，就是帮助教授团队完成候选药物从0到1的转化。戊碳源的项目让我们看到代谢疾病小核酸领域一个具有差异化的科学起点，美迪西愿意做连接这个起点与IND的那座桥。
李斌 教授
戊碳源联合创始人
戊碳源两条管线能够从实验室研究推进至PCC阶段，离不开我们多年来在细胞能量代谢机制研究方面的持续积累、不懈探索与共同努力。从科学研究走向药物研发，不仅需要不断深入回答科学问题，也需要将原创发现系统转化为规范、可行的申报资料。美迪西是本项目的产业合作伙伴，我们期待依托其深厚专业能力，在方案设计、实验推进等方面开展紧密协作，将‘科学上的可能性’进一步转化为‘申报上的可行性’。此次签约后，双方将进一步明确分工、发挥各自优势。戊碳源将继续聚焦管线研究和数据积累，并与美迪西协同推进后续研发及申报工作。
代谢疾病小核酸赛道升温
CRO能力成为转化效率的关键变量
2026年以来，小核酸药物在代谢疾病领域的交易与合作持续升温，MASH和减重成为继罕见病之后备受关注的两大方向。与此同时，肝靶向GalNAc递送技术的成熟，使得小核酸从“概念验证”加速进入“临床前工程化”阶段，对药代动力学、组织分布、免疫原性及毒理学评价的系统性和合规性提出了更高要求。
美迪西在核酸药物领域已搭建覆盖药物发现、药学研究与临床前研究的一体化平台，拥有专业的小核酸研发团队，多个siRNA药物FTE项目已完成或正在推进协议，美迪西将为戊碳源提供符合NMPA与FDA申报要求的非临床药代动力学及安全性评价研究服务，并协助完成IND申报所需的非临床研究资料。
产学研协同的“美迪西样本”：
服务向前延伸，生态向后连接
此次合作的特别之处在于，它不只是一份CRO服务合同。美迪西近年来在产学研融合上持续布局，不断探索“高校成果转化+全链条研发服务”和“项目+平台”的协同模式。与戊碳源的合作，是这一生态在代谢疾病小核酸前沿方向上的进一步落子。
对戊碳源而言，美迪西的角色不仅是服务提供方，更是其在IND申报窗口期内的研发效率保障；对美迪西而言，通过深度绑定具有科学原创性的早期项目，其服务链条从“执行临床前研究”向“参与成果转化进程”延伸。在CRO行业从产能竞争转向能力竞争的背景下，这种“孵化+服务”的深度协同模式，正在成为差异化竞争力的重要来源。
签约同期，美迪西迎来上市七周年。从2019年登陆科创板至今，美迪西已累计服务超2000家客户、助力近700件IND获批临床。七周年之际落子代谢疾病小核酸，既是其前沿平台能力的一次实战检验，也是其产学研生态从“服务交付”走向“价值共创”的又一次尝试。
关于戊碳源
上海戊碳源生物科技有限公司成立于2026年1月，总部位于上海，由上海交通大学医学院知名教授与企业资深药物研发人员联合创立，专注于全新机制的能量代谢调控领域的小核酸药物开发，聚焦肥胖、代谢功能障碍相关脂肪性肝炎（MASH）等能量代谢失衡相关疾病。公司已完成天使轮融资，专利已完成全球主要国家布局，IND申报所需的CMC与非临床评价工作正在推进中，目前新一轮融资已开启。
关于美迪西
美迪西（股票代码：688202.SH）成立于 2004 年，专注于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研发服务。公司构建了覆盖药物发现、药学研究至临床前研究的一站式综合研发平台，并在 ADC/AOC、小核酸、多 (环) 肽、TPD、RIPTAC等前沿领域搭建了服务平台。公司建立了符合国际规范的质量体系，已获得中国 NMPA、美国 FDA、OECD 等 GLP 认证以及 AAALAC 国际认证。目前，公司在上海和Boston拥有约 9.2 万平方米研发实验室。至 2026 年 6 月末，公司已为全球超 2000 家客户提供药物研发服务，参与研发完成的新药项目已有近700 件 IND临床批件。美迪西将继续携手国内外合作伙伴共同推动药物创新，为人类健康贡献力量。欢迎访问公司官网 www.medicilon.com.cn 了解更多详情。
From Shanghai Jiao Tong University Lab toward IND: Medicilon Accelerates PentoGen’s Oligonucleotide Pipeline
November 5, marking Medicilon’s 7th IPO anniversary, Medicilon entered a strategic collaboration agreement with PentoGen. The two parties will jointly conduct preclinical pharmacokinetic and safety assessments for PentoGen’s oligonucleotide pipeline targeting metabolic disorders. Medicilon will deliver one-stop services covering preclinical studies and IND-enabling support to advance academic-originated innovations toward clinical development.
From Lab to IND: The Critical Leap of University Technology Transfer
Founded in January 2026, PentoGen was co-founded by distinguished investigators from Shanghai Jiao Tong University School of Medicine and seasoned drug development professionals.
Building on two decades of fundamental research, the team develops oligonucleotide therapeutics via a novel energy-modulating mechanism to address unmet medical needs in metabolic diseases. Its lead programs target obesity and metabolic dysfunction-associated steatohepatitis (MASH), following a translational path from basic mechanistic findings to candidate molecules.
Chunlin Chen
Chairman and CEO of Medicilon
Universities and research institutions are the source of innovative drugs. As a former professor myself, I know firsthand how difficult the road from laboratory discovery to clinical candidate can be. Medicilon supports academic teams in realizing the 0 to 1 translation of drug candidates. PentoGen’s program offers a scientifically differentiated approach within metabolic oligonucleotide therapeutics, and Medicilon is ready to serve as the bridge leading this promising science to IND submission.
Dr. Chunlin Chen
Chairman and CEO of Medicilon
Universities and research institutions are the source of innovative drugs. As a former professor myself, I know firsthand how difficult the road from laboratory discovery to clinical candidate can be. Medicilon supports academic teams in realizing the 0 to 1 translation of drug candidates. PentoGen’s program offers a scientifically differentiated approach within metabolic oligonucleotide therapeutics, and Medicilon is ready to serve as the bridge leading this promising science to IND submission.
Prof. Bin Li
Professor,Co-founder of PentoGen
Advancing our two pipelines from fundamental research to PCC would not have been possible without our long-term work on cellular energy metabolism. Translating basic science into drug development requires continuous scientific exploration as well as conversion of original findings into regulatory-compliant dossiers. As our partner, Medicilon will collaborate closely on study design and implementation to turn scientific potential into regulatory feasibility. Moving forward, the two teams will leverage complementary strengths: PentoGen will continue pipeline advancement and data generation while working with Medicilon on subsequent R&D and regulatory filings.
As the Metabolic Disease Oligonucleotide Field Heats Up, CRO Capabilities Become a Key Variable in Translation Efficiency
Since 2026, deal-making and partnerships in metabolic disease oligonucleotides have continued to accelerate, with MASH and weight management emerging as the two most closely watched directions after rare diseases. The maturation of liver-targeted GalNAc delivery has moved oligonucleotide programs beyond proof of concept into preclinical engineering, raising requirements for rigorous, standardized evaluation of pharmacokinetics, tissue distribution, immunogenicity and toxicology.
Medicilon has established an integrated oligonucleotide platform spanning drug discovery, CMC and preclinical research, supported by a dedicated oligonucleotide team. Multiple siRNA FTE projects have been completed or in progress. Under this partnership, Medicilon will perform preclinical pharmacokinetic and safety assessments in compliance with NMPA and FDA filing requirements, and help compile preclinical documentation required for IND applications.
Industry–Academia Collaboration: Extending Services Upstream and Building an Innovation Ecosystem
What makes this partnership distinctive is that it goes beyond a conventional CRO service contract. In recent years, Medicilon has invested continuously in industry–academia collaboration, exploring integrated models of "university technology transfer + full-chain development services" and "program + platform." The partnership with PentoGen represents a further step of this ecosystem into the frontier of metabolic disease oligonucleotides.
For PentoGen, Medicilon is not merely a service provider but a guarantee of development efficiency during the critical IND filing window. For Medicilon, deep engagement with original early-stage programs extends our role from executing preclinical studies to participating throughout the translation journey. As the CRO industry shifts focus from capacity to technical expertise, this integrated collaboration creates distinct competitive advantages.
The signing coincides with Medicilon’s seventh anniversary of listing on the STAR Market. Since 2019, Medicilon has served over 2,000 clients and supported nearly 700 IND clearances. Through this metabolic oligonucleotide partnership, Medicilon continues to evolve its industry-academia ecosystem from service delivery toward value co-creation, empowering more early-stage innovations.
About Medicilon
Founded in 2004, Medicilon (Stock Code: 688202.SH) is dedicated to delivering comprehensive preclinical drug R&D services to pharmaceutical enterprises, research institutions, and scientific investigators worldwide. The company has established a one-stop integrated R&D platform encompassing drug discovery, pharmaceutical research, and preclinical research, and has developed service platforms in cutting-edge fields including ADC/AOC, RNAi, peptides (including macrocyclic peptides), TPD, and RIPTAC. The company has instituted a quality system compliant with international standards and has secured GLP certifications from China's NMPA, the U.S. FDA, and the EU's OECD, along with AAALAC International accreditation. At present, the company operates approximately 92,000 square meters of R&D laboratory space across Shanghai and Boston. As of the end of June 2026, the company has provided drug R&D services to over 2,000 clients globally and has supported nearly 700 IND approvals. For more information, visit www.medicilon.com.
评论 (0)